BTCYOTCSurgical & Medical Instruments & ApparatusFiscal year ends March 31
BIOTRICITY INC.
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 19, 2026
$0.05+0.00 (+8.70%)
Close on Oct 19, 2026
- Market cap
- $1.15M
- P/E (TTM)
- –
- Dividend yield
- –
BIOTRICITY INC. revenue by segment
By business segment
By product or service
| Revenue | Q1 27 | Q4 26 | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Technology Fees [Member] | $4.17M | $3.92M | $3.64M | $3.51M | $3.37M | $3.12M | $3.39M | $3.06M | $3.02M | $2.97M | $2.78M | $2.73M | 97.4% | +23.6% |
| Device Sales [Member] | $110.56K | $329.30K | $351.10K | $374.34K | $502.60K | $579.21K | $232.52K | $202.03K | $185.49K | $209.67K | $192.88K | $159.84K | 2.6% | -78.0% |
By region
From the segment and revenue-disaggregation notes of Biotricity's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.